VERAVera Therapeutics, Inc.
Price
+17%1YEnd-of-day closes, not the intraday tick.
RyuScore
Weak, higher than 10% of companiesThe five questions
2 of 5 availableOnly two of the five can be answered for VERA today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.
- Is the business good?not enough filed
- Is it safe?Watch
- Is the price fair?not enough filed
- Is it growing?not enough filed
- What is the market doing?Watch
We are a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Our lead product candidate, atacicept, is currently being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. Atacicept is a native human TACI-Fc fusion protein that binds both the B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL) cytokines and is self-administered subcutaneously at home.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
The next results filing is expected around Nov 4, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 15, 2026Vera Therapeutics Announces TRUTAKNA ™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney.Regulation FD disclosure · press release
- Aug 10, 2026Vera Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results.Earnings release · press release
- Jul 9, 2026On July 9, 2026, Vera Therapeutics, Inc. (the “Company”) announced that William Turner will no longer serve as the Company’s Chief Regulatory Officer and will transition to the role of Special Advisor for Regulatory Affairs, effective as of August 3, 2026.Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.